Looks like Kintor finished enrollment and dosing of phase 1 for gt20029 in China. Chat 8/9/2022
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
View this post in the Community →
Similar Community Posts Join
6 / 348 resultscommunity Husband (35) is thinning on top, he doesn't know yet. Trying to research so he won't feel so lost or upset when I tell him. Help a girl out?
A woman is concerned about her husband's hair thinning and researches treatments like finasteride and minoxidil. He decides against medication due to potential side effects and plans to shave his head if necessary.
community End of Hair loss ( AGA ) ? Since they produce it in china probably we don’t need to wait other 10 yrs😁
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
community Pyrilutamide six months update{ New Progress Pics}
A user shared a six-month update on hair improvement using Pyrilutamide and Minoxidil, noting significant hair regrowth and strength. Some participants questioned the legitimacy of the results and the source of Pyrilutamide.
community Difference: GT20029 vs CosmeRNA
GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.
community Is there a topical androgen receptor blocker so we don't have to fuck with the enzyme and destroy our allopregnanolone, but go and hit the end target straight?
The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.
community Kintor Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
Related Research
6 / 11 results
research Updates in Treatment for Androgenetic Alopecia
New treatments for hair loss include low-dose oral minoxidil, light therapy, and innovative therapies targeting hair growth mechanisms.
research The 100 Most Cited Articles in Androgenetic Alopecia: A Bibliometric Analysis
Recent research on androgenetic alopecia focuses on optimizing treatments, with promising new therapies emerging.
research Efficacy and Safety of Topical GT20029 in Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
GT20029 helps regrow hair in men with hair loss and is well-tolerated.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Androgens and Androgen Receptor in the Management of Skin Diseases
Understanding how androgens and their receptors work can lead to improved treatments for skin diseases.